Differential Regulation of CYP3A4 and CYP3A5 and its Implication in Drug Discovery.

Article Details

Citation

Copy to clipboard

Lolodi O, Wang YM, Wright WC, Chen T

Differential Regulation of CYP3A4 and CYP3A5 and its Implication in Drug Discovery.

Curr Drug Metab. 2017;18(12):1095-1105. doi: 10.2174/1389200218666170531112038.

PubMed ID

28558634 [ View in PubMed

]

Abstract

BACKGROUND: Cancer cells use several mechanisms to resist the cytotoxic effects of drugs, resulting in tumor progression and invasion. One such mechanism capitalizes on the body's natural defense against xenobiotics by increasing the rate of xenobiotic efflux and metabolic inactivation. Xenobiotic metabolism typically involves conversion of parent molecules to more soluble and easily excreted derivatives in reactions catalyzed by Phase I and Phase II drug metabolizing enzymes. METHODS: We performed a structured search of peer-reviewed literature on P450 (CYP) 3A, with a focus on CYP3A4 and CYP3A5. RESULTS: Recent reports indicate that components of the xenobiotic response system are upregulated in some diseases, including many cancers. Such components include the pregnane X receptor (PXR), CYP3A4 and CYP3A5 enzymes. The CYP3A enzymes are a subset of the numerous enzymes that are transcriptionally activated following the interaction of PXR and many ligands. CONCLUSION: Intense research is ongoing to understand the functional ramifications of aberrant expression of these components in diseased states with the goal of designing novel drugs that can selectively target them.

DrugBank Data that Cites this Article

Drug Enzymes

Drug	Enzyme	Kind	Organism	Pharmacological Action	Actions
Erythromycin	Cytochrome P450 3A5	Protein	Humans	Unknown	Substrate Inhibitor	Details
Nicardipine	Cytochrome P450 3A5	Protein	Humans	Unknown	Inhibitor	Details